When the first drugs capable of slowing Alzheimer’s disease won FDA approval, the moment was hailed as a turning point for ...

Critics say the meta-analysis provides an inaccurate picture of anti-amyloid medications. Two of them have FDA approval.

Cyclerion Therapeutics Inc. (NASDAQ:CYCN) is one of the 10 Unstoppable Stocks That Could Double Your Money. Cyclerion ...

A scientific report has raised questions about how much Leqimbi and Kisunla — the “breakthrough” Alzheimer’s drugs that have ...

Alzheimer’s disease, the leading cause of dementia, is a multifactorial disorder involving amyloid beta (Aβ) and tau ...

UCF researchers have uncovered evidence that some movement-related symptoms of Alzheimer's disease may originate outside the ...

A new medical review finds "trivial" benefits for amyloid drugs. See why U.S. experts say these findings may not tell the ...

BUFFALO, N.Y. — Protein droplets serve important biological functions within cells, but in neurodegenerative diseases like ...

Study under fire for mixing data on failed and new anti-amyloid therapies to draw conclusi ...

Drugs once hailed as a breakthrough in the fight against Alzheimer's disease do not meaningfully help patients, a major ...

A major review has provoked a backlash after concluding the medicines provide too little benefit to be noticed.

These drugs were hailed by proponents as breakthroughs in the fight to treat Alzheimer’s disease, but a new independent ...